A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer

Oral Oncol. 2024 Jan:148:106649. doi: 10.1016/j.oraloncology.2023.106649. Epub 2023 Nov 29.

Abstract

Introduction: Head and neck cancer ranks as the seventh most common cancer worldwide. Proton therapy is widely used in head and neck cancer. Osteoradionecrosis(ORN) is currently a commonly investigated side effect of proton therapy. A meta-analysis is needed to investigate this topic.

Material/methods: Two authors searched three databases, including PubMed, Embase, and Cochrane Library; the search period was from inception to June 2023. The search keyword was set to be ((("osteoradionecrosis") OR ("osteonecrosis")) AND ("proton")).

Results: We initially collected 410 articles, and after article selections, 22 articles remained in our systematic reviews. Due to the overlapping of patient populations, 17 studies were finally included in our meta-analysis. The pooled grade 3 or more ORN rate is 0.01(95 % CI = 0.01-0.03). Subgroup analysis showed that IMPT didn't reduce grade 3 or more ORN compared with 3DCPT (p = 0.15).

Conclusions: Our meta-analysis showed that severe ORN rarely occurred in proton therapy for head and neck cancer patients.

Keywords: Head and neck cancer; Osteoradionecrosis; Proton therapy.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Osteoradionecrosis* / etiology
  • Proton Therapy* / adverse effects
  • Retrospective Studies